PMID- 23361189
OWN - NLM
STAT- MEDLINE
DCOM- 20130823
LR  - 20131121
IS  - 1878-5891 (Electronic)
IS  - 0378-5955 (Linking)
VI  - 298
DP  - 2013 Apr
TI  - Spiral ganglion cell morphology in guinea pigs after deafening and neurotrophic 
      treatment.
PG  - 17-26
LID - S0378-5955(13)00027-0 [pii]
LID - 10.1016/j.heares.2013.01.013 [doi]
AB  - It is well known that spiral ganglion cells (SGCs) degenerate in 
      hair-cell-depleted cochleas and that treatment with exogenous neurotrophins can 
      prevent this degeneration. Several studies reported that, in addition, SGC size 
      decreases after deafening and increases after neurotrophic treatment. The 
      dynamics of these cell size changes are not well known. In a first experiment we 
      measured size, shape (circularity) and intracellular density of SGCs in guinea 
      pigs at various moments after deafening (1, 2, 4, 6, and 8 weeks) and at various 
      cochlear locations. In a second experiment, the effect of treatment with 
      brain-derived neurotrophic factor (BDNF) on SGC morphology was investigated at 
      various cochlear locations in deafened guinea pigs. We found that SGC size 
      gradually decreased after deafening in the basal and middle cochlear turns. 
      Already after one week a decrease in size was observed, which was well before the 
      number of SGCs started to decrease. After BDNF treatment SGCs became noticeably 
      larger than normal throughout the cochlea, including the middle and apical turns, 
      whereas an effect on survival of SGCs was primarily observed in the basal turn. 
      Thus, both after deafening and after neurotrophic treatment a change in size 
      occurs before survival is affected. Morphological changes were not restricted to 
      a subpopulation of SGCs. We argue that although changes in cell size and changes 
      in survival might be manifestations of two separate mechanisms, morphological 
      measures such as size, circularity and intracellular density are indicative for 
      survival and degeneration.
CI  - Copyright (c) 2013 Elsevier B.V. All rights reserved.
FAU - van Loon, Maarten C
AU  - van Loon MC
AD  - Department of Otorhinolaryngology and Head & Neck Surgery, Rudolf Magnus 
      Institute of Neuroscience, University Medical Center Utrecht, P.O. Box 85500, 
      3508 GA Utrecht, The Netherlands.
FAU - Ramekers, Dyan
AU  - Ramekers D
FAU - Agterberg, Martijn J H
AU  - Agterberg MJ
FAU - de Groot, John C M J
AU  - de Groot JC
FAU - Grolman, Wilko
AU  - Grolman W
FAU - Klis, Sjaak F L
AU  - Klis SF
FAU - Versnel, Huib
AU  - Versnel H
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130126
PL  - Netherlands
TA  - Hear Res
JT  - Hearing research
JID - 7900445
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 59-01-8 (Kanamycin)
RN  - 7LXU5N7ZO5 (Furosemide)
SB  - IM
MH  - Animals
MH  - Auditory Threshold
MH  - Brain-Derived Neurotrophic Factor/*pharmacology
MH  - Cell Shape/drug effects
MH  - Cell Size/drug effects
MH  - Cell Survival/drug effects
MH  - Deafness/chemically induced/*drug therapy/pathology
MH  - Disease Models, Animal
MH  - Female
MH  - *Furosemide
MH  - Ganglia, Spinal/*drug effects/pathology
MH  - Guinea Pigs
MH  - Hair Cells, Auditory/drug effects/pathology
MH  - *Kanamycin
MH  - Nerve Degeneration
MH  - Neurons/*drug effects/pathology
MH  - Time Factors
EDAT- 2013/01/31 06:00
MHDA- 2013/08/24 06:00
CRDT- 2013/01/31 06:00
PHST- 2012/04/04 00:00 [received]
PHST- 2012/12/21 00:00 [revised]
PHST- 2013/01/17 00:00 [accepted]
PHST- 2013/01/31 06:00 [entrez]
PHST- 2013/01/31 06:00 [pubmed]
PHST- 2013/08/24 06:00 [medline]
AID - S0378-5955(13)00027-0 [pii]
AID - 10.1016/j.heares.2013.01.013 [doi]
PST - ppublish
SO  - Hear Res. 2013 Apr;298:17-26. doi: 10.1016/j.heares.2013.01.013. Epub 2013 Jan 
      26.